### Session 1  New Insights into the Pathogenesis of Aortic Aneurysm from Disease Genes and Animal Models  
**Cheryl Maslen, PhD, Chair**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Developmental underpinnings of apparently acquired aortic aneurysm</td>
</tr>
<tr>
<td></td>
<td>Hal Dietz, MD, Johns Hopkins Univ., Howard Hughes Medical Institute, Baltimore, MD</td>
</tr>
<tr>
<td>9:20</td>
<td>Perturbation of the VSMC contractile unit and aortic aneurysm: clinical presentation, incidence and mechanism</td>
</tr>
<tr>
<td></td>
<td>Dianna Milewicz, MD, PhD, Univ. of Texas Health Science Center, Houston, TX</td>
</tr>
<tr>
<td>9:40</td>
<td>Notch signaling and aortic disease</td>
</tr>
<tr>
<td></td>
<td>Vidu Garg, MD, Nationwide Children’s Hospital, Columbus, Ohio</td>
</tr>
<tr>
<td>10:00</td>
<td>Angiotensin II induction of thoracic and abdominal experimental aneurysms</td>
</tr>
<tr>
<td></td>
<td>Alan Daugherty, PhD, DSc, Univ. of Kentucky, Lexington, KY</td>
</tr>
<tr>
<td>10:20</td>
<td>Question and Answer</td>
</tr>
<tr>
<td>10:35</td>
<td>Break</td>
</tr>
<tr>
<td>10:50</td>
<td>Potential Activators of Latent TGFβ in Marfan syndrome</td>
</tr>
<tr>
<td></td>
<td>Daniel Rifkin, PhD, New York Univ., New York, NY</td>
</tr>
<tr>
<td>11:10</td>
<td>AngII infusion and vascular inflammation through IL6 signaling in the mouse model</td>
</tr>
<tr>
<td></td>
<td>Allan Brasier, MD, Univ. of Texas Medical Branch, Galveston, TX</td>
</tr>
<tr>
<td>11:30</td>
<td>Phenotype-genotype and genotype-functional correlations in inherited aneurysm conditions</td>
</tr>
<tr>
<td></td>
<td>Bart Loeys, MD, PhD, Ghent Univ. Hospital, Ghent Belgium</td>
</tr>
<tr>
<td>11:50</td>
<td>Transcriptional regulation of coronary artery development</td>
</tr>
<tr>
<td></td>
<td>Craig Bascom, MD, PhD, Weill Medical College of Cornell Univ., New York, NY</td>
</tr>
<tr>
<td>12:10</td>
<td>Question and Answer</td>
</tr>
<tr>
<td>12:30–1:10</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
2:30 Question and Answer
2:50 Break

Session 3  Gaps in the Natural History of Aortic Disease
Reed Pyeritz, MD, PhD, Chair

3:10 Incidence and outcome of aortic disease in Turner syndrome  
Michael Silberbach, MD, Doernbecher Children’s Hospital, Portland, OR

3:25 Aortic dilation in Turner syndrome: progression over time and response to pharmacologic treatment  
Carolyn Bondy, MD, National Institutes of Health, Bethesda, MD

3:40 Aging and predisposition in Marfan syndrome  
Reed Pyeritz, MD, PhD, Univ. of Pennsylvania Medical Center, Philadelphia, PA

4:00 Phenotypic heterogeneity and determinants in aortic aneurysm syndromes  
Guillaume Jondeau, MD, Hospital Bichat, Paris, France

4:20 Clinical association of intracranial and aortic aneurysms: a shared genetic basis?  
Dong Kim, MD, Univ. of Texas Health Science Center, Houston, TX

4:40 Population prevalence of TAA and its relation to CV risk factors  
Richard Devereux, MD, Weill Medical College of Cornell Univ., New York, NY

5:00 Question and Answer

Day 2  Wednesday, September 23, 2009

8:00 Continental Breakfast

Session 4  Controversies and Opportunities in the Surgical Management of Aortic Disease
Scott LeMaire, MD, and Howard Song, MD, PhD, Co-Chairs

8:30 Surgical considerations regarding the proximal aorta in bicuspid aortic valve syndrome and other non-Marfan entities  
Joseph Bavaria, MD, Univ. of Pennsylvania Medical School, Philadelphia, PA

8:45 Early outcomes after valve-sparing root replacement: report from the Aortic Valve Operative Outcomes in Marfan Patients Registry  
Joseph Coselli, MD, Baylor College of Medicine, Houston, TX

9:00 Utility of the Ross procedure in inherited ascending aortic aneurysm  
Giovanni Battista Luciani, MD, Univ. of Verona, Verona, Italy

9:20 Current strategies for follow-up and treatment for Ehlers-Danlos syndrome type IV, the “vascular” type  
Peters Byers, MD, Univ. of Washington, Seattle, WA

9:35 A critical assessment of surgical/interventional practices in vascular EDS  
James H. Black, MD, Johns Hopkins Univ., Baltimore, MD

9:50 Question and Answer

10:10 Break

10:30 The role of thoracic endografts in acute aortic syndromes  
Lars Svensson, MD, PhD, Cleveland Clinic, Cleveland, OH

10:50 Development of rational surgical practices in patients with TGFβ mutations  
Duke Cameron, MD, Johns Hopkins School of Medicine, Baltimore, MD

11:10 Question and Answer
Session 5  Late-breaking science  
Richard Devereux, MD, Chair

11:20  Deletion of Acta2 Leads to Increased Smooth Muscle Cell Proliferation and Neointimal Formation in Mice  
Christina L. Papke  Univ. of Texas Health Science Center, Houston, TX

11:30  Analysis of TGFbeta Function in Aortic Aneurysms  
Mohamad Azhar, PhD  Univ of Arizona, Tucson AZ

11:40  Chromosome 16p13.1 duplications encompassing MYH11 gene in sporadic patients with thoracic aortic aneurysms and dissections
Shao-Qing Kuang, MD, PhD  Univ. of Texas Health Science Center, Houston, TX

11:50  Membrane type-1 matrix metalloproteinase plays a multifunctional role in thoracic aortic aneurysm development.
Jeffrey A. Jones PhD, Medical University of South Carolina, Charleston, SC

12:00  Smooth muscle cells of fibulin-4 deficient mice contribute to aneurysm progression: An animal model for human thoracic aortic aneurysms
Hiromi Yanagisawa, MD, PhD, Univ. of Texas Southwestern Medical Center, Dallas, TX

12:10  Question and Answer

Session 6  Working Lunch  
Dianna Milewicz, MD, PhD, and Craig Basson, MD, PhD, Co-Chairs

12:20  GenTAC investigators and others interested get together and reset registry research priorities based on the presentations given. Where do we need to move the science (current and future)?

Session 7  Novel Medical Therapeutic Strategies in the Treatment of Aortic Disease  
Hal Dietz, MD, Chair

2:40  AT2 signaling and aortic aneurysm
Jennifer Habashi, MD, The Johns Hopkins Hospital, Baltimore, MD

3:00  Novel therapeutic targets in Marfan syndrome
Hal Dietz, MD, Johns Hopkins Univ., Howard Hughes Medical Institute, Baltimore, MD

3:20  Emerging therapeutics to attenuate TGFβ signaling
John McPherson, PhD, Genzyme Corporation, Cambridge, MA

3:40  Question and Answer

4:00  Angiotensin receptor blockers: opportunities and limitations
Robert Thompson, MD, Washington Univ. School of Medicine, St. Louis, MO

4:20  Assessment of infrastructure for clinical trials in vascular disease
Patrice Desvigne-Nickens, MD, National Heart, Lung and Blood Institute, Bethesda, MD

4:40  Question and Answer

5:00 PM  Closing Remarks

The following organizations provided unconditional grants to help make the Aortic Disease Summit possible:
Office of Rare Diseases Research
W.L. Gore & Associates, Inc.
Medtronic Endovascular Innovations
National Marfan Foundation